PMID: 26320436Sep 1, 2015Paper

Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer

Asian Pacific Journal of Cancer Prevention : APJCP
Y KawaiH Matsuyama

Abstract

Factors predictive of survival have been identified in Western patients with metastatic clear cell renal cell carcinoma (mCCRCC) treated with sunitinib. Less is known, however, about factors predictive of survival in Japanese patients. This study evaluated factors prognostic of survival in Japanese patients with mCCRCC treated with first-line sunitinib. This retrospective study evaluated 46 consecutive Japanese mCCRCC patients treated with sunitinib as first line therapy. Clinical and biochemical markers associated with progression-free survival (PFS) were analyzed, with prognostic factors selected by uni- and multivariate Cox regression analyses. Univariate analysis showed that factors significantly associated with poor PFS included Memorial Sloan-Kettering Cancer Center poor risk scores, International Metastatic RCC Database Consortium poor risk and high (>0.5 mg/dl) serum C-reactive protein (CRP) concentrations (p<0.001 each). Multivariate analysis showed that high serum CRP was independently associated with poorer PFS (p=0.040). Six month disease control rate (complete response, partial response and stable disease) in response to sunitinib was significantly higher in patients with normal (≤0.5 mg/dl) than elevated baseline ...Continue Reading

References

Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J MotzerMadhu Mazumdar
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Oct 3, 2009·The Lancet Oncology·Brian I Rini, Michael B Atkins
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Sep 17, 2010·Cancer·Manuela SchmidingerChristoph C Zielinski
Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
Jun 8, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Tetsuo FujitaShiro Baba
Aug 7, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Atsunari KawashimaUNKNOWN Osaka Renal Cell Carcinoma Clinical Study Collaboration
May 30, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Jin DaiZhang-Qun Ye
May 30, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Seyda GunduzHakan Bozcuk

❮ Previous
Next ❯

Citations

Sep 27, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshio Ohno
Sep 24, 2019·Anesthesia Progress·Atsushi NakajimaTatsuki Kinoshita
Jan 22, 2020·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Guiya JiangMing Chen
Oct 23, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Kenichi HaradaHirotsugu Uemura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.